Sotalol
Appearance
Clinical data | |
---|---|
Trade names | Betapace, Sorine, Sotylize, others[1] |
AHFS/Drugs.com | Monograph |
MedlinePlus | a693010 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
Drug class | Beta blocker |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 90–100%[2] |
Metabolism | Not metabolized[2] |
Elimination half-life | 12 hours[2] |
Excretion | Kidney Mammary gland (In lactating individuals)[2] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C12H20N2O3S |
Molar mass | 272.36 g·mol−1 |
3D model (JSmol) | |
Chirality | Racemic mixture |
| |
| |
(verify) |
Sotalol (brand names Betapace, Betapace AF, Sorine, and Sotylize) belongs to a group of medicines called beta blockers. It is used to treat atrial fibrillation and other conditions that cause an irregular heartbeat (arrhythmia).[3] It starts to work after about 4 hours, but it can take 2 to 3 days to fully take effect.[3]
Related pages
[change | change source]References
[change | change source]- ↑ "Sotalol Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 18 March 2019.
- ↑ 2.0 2.1 2.2 2.3 U.S. Food and Drug Administration (July 2009). "Sotalol: Full Prescribing Information" (PDF). Retrieved 23 April 2015.
- ↑ 3.0 3.1 "Sotalol: medicine to treat an irregular heartbeat". nhs.uk. 2018-08-29. Retrieved 2024-06-05.